Merkel cell carcinoma (MCC) is a rare, aggressive form of skin cancer that develops in the Merkel cells, which sit just below the skin’s surface and help you sense light touch and pressure. About 3,000 people are diagnosed with it in the United States each year, making it far less common than melanoma or other skin cancers, but significantly more dangerous for its size. It grows fast, spreads early, and often goes unrecognized because it doesn’t look like what most people picture when they think of skin cancer.
What It Looks Like
MCC typically appears as a firm, painless bump on the skin. The most common color is red or pink, seen in about 56% of cases, followed by a blue or violet shade in roughly 26%. It doesn’t itch, bleed, or hurt in most cases. That lack of symptoms is actually one of its hallmarks: 88% of lesions cause no tenderness at all, which is part of why people delay getting them checked.
The bumps tend to be small at first. About one in five are under 1 centimeter at diagnosis (smaller than a pencil eraser), while the majority fall between 1 and 2 centimeters. What sets MCC apart from a harmless bump is speed. Nearly two-thirds of patients report that the lesion grew noticeably within three months. A painless, reddish lump on sun-exposed skin that’s getting bigger quickly is the classic warning pattern.
Dermatologists sometimes use the acronym AEIOU to remember the typical profile: Asymptomatic (no pain), Expanding rapidly, Immunosuppressed patient, Older than 50, and UV-exposed fair skin. A lesion that checks several of those boxes warrants a biopsy.
Causes and Risk Factors
A virus plays a central role. The Merkel cell polyomavirus, a common and usually harmless virus that most people carry on their skin, is found integrated into the tumor DNA in roughly 80% of MCC cases. When the virus’s genetic material inserts itself into a cell’s genome, it can produce proteins that override normal cell growth controls and drive cancer development. The remaining 20% of cases are virus-negative and instead carry high numbers of UV-related DNA mutations.
Ultraviolet radiation is the single largest population-level risk factor. An analysis of nearly two decades of U.S. data estimated that about 65% of all MCC cases are attributable to UV exposure, with the highest rates among fair-skinned individuals living in areas with greater sun intensity. The cancer overwhelmingly affects light-skinned people: 98% of patients in one large study had fair skin, and 81% had tumors on sun-exposed areas like the head, neck, or arms.
Age matters too. Ninety percent of patients are over 50, and the median age at diagnosis is 77. Men are diagnosed more often than women.
A weakened immune system dramatically raises risk. Solid organ transplant recipients, who take medications to suppress their immune system, face a 16- to 24-fold increase in MCC incidence compared to the general population. People with chronic lymphocytic leukemia have an 8- to 16-fold increase. Those living with HIV carry about a 3-fold elevated risk and tend to be diagnosed much younger, at a median age of 56 rather than 77.
How It Is Diagnosed and Staged
Diagnosis starts with a skin biopsy. Because MCC can resemble a cyst, a benign growth, or even another type of cancer under the microscope, pathologists use special staining techniques to confirm the diagnosis. Once confirmed, imaging scans help determine whether the cancer has spread beyond the skin.
A sentinel lymph node biopsy is a key part of staging. In this procedure, the first lymph node that drains the area around the tumor is identified, removed, and examined for cancer cells. A negative result suggests the cancer hasn’t spread to nearby lymph nodes. A positive result means cancer cells have reached the node, which changes both the stage assignment and the treatment plan.
The staging system for MCC is unusual because it distinguishes between patients who have had their lymph nodes pathologically examined and those who haven’t. If you’ve had a sentinel lymph node biopsy that comes back negative, you’re classified as stage IA or IIA, which carries a better prognosis. If your lymph nodes only appear normal on a physical exam or imaging (without biopsy confirmation), you’re classified as stage IB or IIB, because undetected microscopic spread may be present. Tumor size also matters: tumors 2 centimeters or smaller are classified as T1, those between 2 and 5 centimeters as T2, those larger than 5 centimeters as T3, and tumors invading deeper structures like muscle or bone as T4.
Treatment Approaches
For localized MCC (stages I and II), surgery is the primary treatment. Surgeons typically remove the tumor with a margin of 1 to 3 centimeters of surrounding tissue. If lymph nodes test positive, a more extensive lymph node removal follows.
Radiation therapy is commonly used after surgery. Adjuvant radiation to the tumor bed has been shown to significantly reduce the chance of the cancer returning locally and to improve survival. The standard adjuvant dose is around 50 Gy, delivered in daily fractions over several weeks, though the exact dose may be adjusted based on whether the surgical margins were clear and the location of the tumor.
For advanced or metastatic MCC, immunotherapy has transformed outcomes. Pembrolizumab, a checkpoint inhibitor that helps the immune system recognize and attack cancer cells, received FDA approval for recurrent or metastatic MCC in 2018. In the clinical trial that led to approval, 56% of patients saw their tumors shrink, and 24% achieved a complete response, meaning no detectable cancer remained. Among those who responded, 96% maintained their response for longer than six months, and more than half still had ongoing responses past one year. The treatment works by blocking a protein that cancer cells use to hide from the immune system.
Survival Rates by Stage
Prognosis depends heavily on how far the cancer has spread at diagnosis. For patients with pathologic stage I disease, the MCC-specific five-year survival rate is 95%. That drops to 41% for stage IV, where the cancer has spread to distant sites. For patients with stage I or II disease who later develop a local recurrence near the original tumor site, survival remains relatively favorable at around 85% at five years, compared with 88% for those with no recurrence at all. In other words, catching a local recurrence early doesn’t dramatically worsen the overall outlook.
Recurrence and Monitoring
MCC recurs more often than many other skin cancers. In a large study of 618 patients, 40% experienced a recurrence after initial treatment. The critical window is the first three years: approximately 95% of all recurrences appear within that timeframe, with the highest risk concentrated between years one and three. After three years, the risk drops substantially, though it never reaches zero.
Because of this pattern, close follow-up during those first three years is essential. Monitoring typically involves regular physical exams and imaging scans. For the roughly 80% of patients whose tumors are linked to the Merkel cell polyomavirus, a blood test called the AMERK panel can add another layer of surveillance. This test measures antibodies your body produces against the virus’s cancer-driving proteins. After successful treatment, antibody levels typically drop. If they later rise, recurrence is highly likely: rising AMERK titers have a 99% positive predictive value for detecting returning disease. For seropositive patients, testing every three to four months alongside routine imaging is recommended during the surveillance period.
This combination of blood testing and imaging can catch recurrences before they become visible or cause symptoms, which is particularly valuable for a cancer where early detection of recurrence translates directly into better treatment options.